Pfizer plans European launch of Lyme disease vaccine, timing under discussion
Pfizer and its partner Valneva are preparing to submit a Lyme disease vaccine for regulatory approval, with Europe expected to be the first market. Executives said the European Medicines Agency received the application in August and the CHMP will issue a decision in 2027, while a separate report claims Pfizer aims to launch in Europe in November 2026. The company also indicated ongoing discussions with the U.S. FDA about a filing that could be completed by year‑end.
Why it matters
The European launch could add a new revenue stream for Pfizer, but the exact timing remains uncertain, affecting sales forecasts. Investors should watch the EMA decision timeline and any update on the U.S. filing.
Key facts
- 1The EMA confirmed receipt of Pfizer’s Lyme vaccine application in August. biospace.com
- 2The CHMP is scheduled to deliver its verdict in 2027. biospace.com
- 3Pfizer plans to launch the vaccine in Europe in November 2026. geneonline.com
- 4Pfizer is discussing a U.S. FDA submission that analysts suggest could be completed by the end of the year. biospace.com
Open questions
- Launch date conflict: November 2026 launch claim vs EMA decision expected in 2027.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.